Overview A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus Status: Not yet recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary A Study to Assess the effect of CT-868 in hemoglobin A1c (HbA1c) in Overweight and Obese Participants with Type 2 Diabetes Mellitus. Phase: Phase 2 Details Lead Sponsor: Carmot Therapeutics, Inc.